ARTICLE | Finance

Pollen for Anergis

Series B to move Anergis to Phase III with rapid vaccine for birch pollen allergy

December 15, 2014 8:00 AM UTC

By topping off its series B financing, Anergis S.A. hopes to make its short-term birch pollen allergy vaccine into a long-term winner. The additional CHF14.5 million ($15 million) in funding brings the series B total to CHF23 million ($24.5 million).

Existing investors Sunstone Capital, BioMedInvest and Renaissance PME led the second close with new investor WJFS. Two undisclosed U.S.-based family offices, also new investors, participated...